Menu
Search Close

News

Posting of Circular

11th March 2016

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF IRELAND, THE RUSSIAN FEDERATION OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.

FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND SHALL NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR THE SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY ORDINARY SHARES OF SCANCELL IN ANY JURISDICTION IN
WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT SHOULD BE READ IN ITS ENTIRETY. IN PARTICULAR, YOU SHOULD READ AND UNDERSTAND THE INFORMATION PROVIDED IN THE "IMPORTANT NOTICES" SECTION AND IN THE APPENDICES.

Scancell Holdings Plc (LSE:AIM SCLP) ("Scancell" or the "Company"), the developer of novel immunotherapies for the treatment of cancer, further to the announcement on 9 March of the successful Firm Placing to raise £3.4 million, will today publish a circular setting out, amongst other things, details of the Open Offer.

The Open Offer is for up to approximately 22.5 million New Ordinary Shares at 17 pence per New Ordinary Share to raise up to £3.8 million, which will provide Qualifying Shareholders with the opportunity
to subscribe for New Ordinary Shares on the basis of:

1 New Ordinary Share for every 10 Existing Ordinary Shares held

The Firm Placing and Open Offer are within the Company’s existing allotment authorities. The Circular to shareholders will be available shortly on the Company's website at www.scancell.co.uk.

For further information please contact:

Scancell Holdings Plc

Dr Richard Goodfellow, Joint CEO

Professor Lindy Durrant, Joint CEO

+ 44 (0) 20 3727 1000

Panmure Gordon (Nominated Adviser and placing agent)

Robert Naylor/Paul Fincham, Corporate Finance

Maisie Atkinson, Sales

+44 (0) 20 7886 2500

Lesmoir-Gordon, Boyle & Co. Limited (Sub placing agent)

Angus Grierson

+44 (0) 207 518 9892

FTI Consulting

Mo Noonan

Simon Conway

+ 44 (0) 20 3727 1000


Panmure Gordon (UK) Limited is acting as Nominated Adviser and placing agent in respect of the Placing. Lesmoir-Gordon, Boyle & Co. Limited is acting as sub placing agent.

Expected Timetable of Principal Events

Announcement of the Firm Placing and Open Offer

9 March

Record Date for the Open Offer

9 March

Publication of the Open Offer document and the Application Form

11 March

Ex-entitlement Date

11 March

Open Offer Entitlements credited to CREST stock accounts of Qualifying CREST Holders

14 March

Recommended last time and date for requesting withdrawal of Open Offer Entitlements from CREST

4.30p.m. on 21 March

Latest time and date for depositing Open Offer Entitlements into CREST

3.00p.m. on 22 March

Latest time and date for splitting Application Forms

(to satisfy bona fide market claims only)

3.00p.m. on 23 March

Latest time and date for acceptance of the Open Offer and receipt of completed Application Forms

11.00 a.m. on 29 March

Announcement of result of Open Offer

31 March

Admission and commencement of dealings in the New Ordinary Shares 

8.00 a.m. on 5 April

New Ordinary Shares credited to CREST members’ account

5 April

Despatch of definitive share certificates for New Ordinary Shares in certificated form

19 April

 

The above time and/or dates are subject to change and, in the event of such change, the revised times and/or dates will be notified to Shareholders by an announcement through a Regulatory Information
Service.

Dealing codes

The ISIN of the Open Offer Entitlement is GB00BDGSNM16
The ISIN of the Excess Application Facility is GB00BDGSNP47
All defined terms used in this announcement are defined, unless otherwise defined here, in the Proposed Placing and Open Offer announcement made on 9 March 2016.

Webcasts, Interviews and Media Coverage

Scancell Holdings wins Japanese patent protection

It follows on from similar awards in key markets such as the US, Europe, South Africa and Australia

Mon, 08 Apr 2019 08:20:00

Scancell strengthens IP with two “important” patent grants in US and Europe

The US patent covers Modi-1, while the European patent relates to a monoclonal antibody called FG88

Wed, 20 Mar 2019 07:55:00

Scancell in vanguard of immuno-oncology advances, with two technologies that show early promise

The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise

Tue, 12 Feb 2019 15:07:00